Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Gastrointestinal 1

Conditions

Kidney Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 23Nivolumab 20atezolizumab 10Specimen Handling 8Ipilimumab 8Cyclophosphamide 8cabozantinib 6Magnetic Resonance Spectroscopy 6fludarabine 5Sorafenib 5sargramostim 4Trastuzumab 4Sunitinib 4Bevacizumab 4lenvatinib 3enzalutamide 3durvalumab 3avelumab 3X-Rays 3Paclitaxel 3Fluorodeoxyglucose F18 3Docetaxel 3Albumin-Bound Paclitaxel 3ulixertinib 2spartalizumab 2relatlimab 2regorafenib 2palbociclib 2epacadostat 2cemiplimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Blood Cell Count × Genitourinary × Clear all
NCT07485114 2026-03-20

Association Between Galectin-3 Levels and Outcomes in Patients With Renal Cell Carcinoma, Transitional Cell Carcinoma , Non Small Cell Lung Cancer, and Hepatocellular Carcinoma, Treated With PD-1/PDL-1 Inhibitors

Tel-Aviv Sourasky Medical Center

Recruiting
300 enrolled
GastrointestinalGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinoma, Hepatocellular, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡